MK, I accidently hit that button to be honest. Apologies my...

MK, I accidently hit that button to be honest. Apologies my mistake. Still no position.

For QRX, the situation is shaping up favourably - in a play dough kind of way. For context, the risk with QRX is approval and/or path to approval this time around. What sticks out most in my mind is the opportunity to influence the FDA decision. In many respects the product is moving into unchartered territory, for all parties concerned. I actually see this as an advantage. Essentially QRX has provided all information and more, so that in JH's mind there is only one option and that is too approve. I am looking at QRX from this 'higher-level' rather than the lower level detail. Identifying this has helped me single out the business as an opportunity - misunderstood and outstanding. No doubt others will be thinking the same thing.

I see this as a distinguishing factor from other hopefuls in the sector.